Astral Systems

Investor: Mercia Ventures

Bristol-based Astral Systems, a deep-tech company specializing in nuclear fusion technology for medical applications, has successfully raised £23 million in the first close of its Series A investment round. Summary of transaction details: Value: £23 million Sector: Healthcare & Biotech Advisor: Not explicitly mentioned Key Entities: Astral Systems (Target), Mercia Ventures (Lead Investor), Tees River, Daphni, Blast Club, Speedinvest, Playfair Capital (Co-investors) Location: Bristol, UK (Target Company) Note: This funding will accelerate Astral Systems' development of medical isotopes crucial for cancer diagnosis and treatment, expand its modular reactor production, and advance its fusion research, addressing critical shortages in the healthcare sector.

Investor: Mercia Ventures

Astral Systems has secured a £23m Series A funding round led by Mercia Ventures to scale its nuclear fusion technology.Summary of transaction details:Value: £23mSector: DeepTech & AIAdvisor: Not disclosedKey Entities: Astral Systems, Mercia VenturesLocation: Bristol, UKNote: This funding round will support Astral Systems' plans to bring critical medical isotopes to market and advance fusion research, demonstrating the growing interest in deep tech and nuclear fusion technology.

Investor: Mercia Ventures

Astral Systems, a Bristol-based deep-tech company, has secured £23 million in Series A funding to develop nuclear fusion technology. Summary of transaction details: Value: £23 million Sector: DeepTech & AI Advisor: null Key Entities: Astral Systems, Mercia Ventures Location: Bristol Note: Astral Systems' proprietary multi-state fusion technology aims to tackle shortages of medical isotopes used in cancer diagnosis and treatment.